L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 327.1 ILS -6.89% Market Closed
Market Cap: 164.5m ILS

EV/EBIT
Enterprise Value to EBIT

0
Current
-0.2
Median
5
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
0
=
Enterprise Value
-34.6k ILS
/
EBIT
-21.3m USD
EBIT Growth EV/EBIT to Growth
US
L
Lineage Cell Therapeutics Inc
TASE:LCTX
Average EV/EBIT: 16.9
0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 464.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.1
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.2 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.9
17%
1.2
AU
CSL Ltd
ASX:CSL
23.5
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
11%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -298.2 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.1 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
0
2-Years Forward
EV/EBIT
0
3-Years Forward
EV/EBIT
0